Cargando…

Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data

BACKGROUND: The economic burden of ulcerative colitis (UC), specifically related to indirect costs, is not extensively documented. Understanding and quantifying it is required by health care decision makers. AIM: To assess the impact of indirect costs of UC in observation studies. METHOD: A systemat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Constantin, Joelle, Atanasov, Petar, Wirth, Daniel, Borsi, Andras
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842452/ https://www.ncbi.nlm.nih.gov/pubmed/31706270 http://dx.doi.org/10.1186/s12876-019-1095-9

Ejemplares similares

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis
por: Singh, Harpreet, et al.
Publicado: (2023)

The cost burden of Crohn’s disease and ulcerative colitis depending on biologic treatment status – a Danish register-based study
por: Alulis, Sarah, et al.
Publicado: (2021)

Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2017)

Indirect costs of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. A systematic review
por: Kawalec, Paweł
Publicado: (2016)

Real-World Prescription Pattern and Healthcare Cost Among Patients with Ulcerative Colitis in Japan: A Retrospective Claims Data Analysis
por: Miyazaki, Celine, et al.
Publicado: (2021)

Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review
por: Luttropp, Karin, et al.
Publicado: (2020)

Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis
por: Lucaciu, Laura A., et al.
Publicado: (2021)

Treatment patterns, persistence with therapy, and outcomes of ustekinumab in Crohn's disease: Real‐world data analysis
por: Banon, Tamar, et al.
Publicado: (2022)

Correction to: Real-World Prescription Pattern and Healthcare Cost Among Patients with Ulcerative Colitis in Japan: A Retrospective Claims Data Analysis
por: Miyazaki, Celine, et al.
Publicado: (2021)

Cost Burden of Crohn’s Disease and Ulcerative Colitis in the 10-Year Period Before Diagnosis—A Danish Register-Based Study From 2003–2015
por: Vadstrup, Kasper, et al.
Publicado: (2020)

Real-world effectiveness of ustekinumab for patients with ulcerative colitis: a systematic review and meta-analysis
por: Uchida, Genta, et al.
Publicado: (2023)

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
por: Uchida, Genta, et al.
Publicado: (2023)

Extraintestinal Manifestations and Other Comorbidities in Ulcerative Colitis and Crohn Disease: A Danish Nationwide Registry Study 2003–2016
por: Vadstrup, Kasper, et al.
Publicado: (2020)

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
por: Teich, Niels, et al.
Publicado: (2020)

Work-Related Productivity Loss and Associated Indirect Costs in Patients With Crohn’s Disease or Ulcerative Colitis in the United States
por: Ding, Zhijie, et al.
Publicado: (2022)

A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis
por: Stawowczyk, Ewa, et al.
Publicado: (2017)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
por: Nakamura, Shiro, et al.
Publicado: (2022)

Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
por: Thunberg, Joel, et al.
Publicado: (2022)

Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure
por: Bressler, Brian, et al.
Publicado: (2018)

Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2021)

Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
por: Beilman, Candace L., et al.
Publicado: (2016)

Cost-effectiveness of biological treatment of ulcerative colitis – a systematic review
por: Stawowczyk, Ewa, et al.
Publicado: (2017)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
por: D’Amico, Ferdinando, et al.
Publicado: (2019)

Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
por: Zingone, Fabiana, et al.
Publicado: (2020)

Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis
por: Ishida, Natsuki, et al.
Publicado: (2021)

The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
por: Ye, Byong Duk, et al.
Publicado: (2021)

Significance of diagnosis and prognosis for appendiceal orifice inflammation in ulcerative colitis: a real-world study
por: Deng, Peng, et al.
Publicado: (2022)

Real‐world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey
por: Nardone, Olga Maria, et al.
Publicado: (2023)

Real-World Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients: A Retrospective Cohort Study
por: State, Monica, et al.
Publicado: (2023)

Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis
por: Walsh, Alissa, et al.
Publicado: (2019)

Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010-2016 in Hungary – a population-based study
por: Kunovszki, Péter, et al.
Publicado: (2020)

MarvelD3 Is Upregulated in Ulcerative Colitis and Has Attenuating Effects during Colitis Indirectly Stabilizing the Intestinal Barrier
por: Weiß, Franziska, et al.
Publicado: (2022)

Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings
por: Okayasu, Motohiro, et al.
Publicado: (2019)

Remote Monitoring of Patient-Reported Outcomes in Ulcerative Colitis: A Prospective Real-World Pilot Study
por: Sebastian, Shaji, et al.
Publicado: (2019)

Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford
por: Pulusu, Samba Siva Reddy, et al.
Publicado: (2020)

Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
por: Long, Millie D, et al.
Publicado: (2020)

Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative Colitis
por: Chun, Jaeyoung
Publicado: (2021)

Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China
por: Huang, Kaituo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gn6oggvubmffu1ps61ovi6nrv2